News
-
-
-
PRESS RELEASE
HAMBORNER REIT AG publishes preliminary figures – stable and planned business development in 2024 – Dividend proposal at previous year's level
HAMBORNER REIT AG publishes preliminary figures for 2024 showing stable business development with a 2.0% increase in rental income. Dividend proposal remains unchanged at €0.48 per share -
REGULATED PRESS RELEASE
Biophytis announces its participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)
Biophytis to participate in ICFSR 15th International Conference on Frailty and Sarcopenia Research, presenting data on BIO101 for obesity-associated sarcopenia. Event in Toulouse, March 12-14 -
-
PRESS RELEASE
PSP Swiss Property achieves very good operating results and increases the dividend to CHF 3.90 per share.
PSP Swiss Property achieves very good operating results and increases the dividend to CHF 3.90 per share. The real estate market remained robust with improvements in transaction markets -
PRESS RELEASE
First half of the financial year 2024/25: Strong organic growth and margin expansion continue – strategy execution on track
dormakaba Holding AG reports strong organic growth and margin expansion in the first half of the financial year 2024/25. The company's strategy execution is on track -
PRESS RELEASE
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®. Approval for treating retinal diseases granted by UK's MHRA -
-
PRESS RELEASE
UniDoc - Announces Filing of Amended and Restated Interim Management Discussion and Analysis
UniDoc Health Corp. issues amended and restated management's discussion and analysis for clarifying disclosure following continuous disclosure review by the British Columbia Securities Commission
